instituto Portugues de Oncologia Porto Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02385019
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institute of Oncology of Porto, Portugal | Instituto Portugues de Oncologia, Francisco Gentil, Porto | Instituto Portugues de Oncologia Lisboa: Portugal | instituto Portugues de Oncologia Porto: Portugal

Active Ingredients

Drugs in Phase 2 Trials (2)

donor regulatory t lymphocytes (1 trial)

durvalumab (imfinzi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2